NEUROCRINE BIOSCIENCES INC

For the period ended Dec 31, 2025. Filed Feb 11, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 11, 2026

NBIX$169.14+0.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Income and Comprehensive Income

AND COMPREHENSIVE INCOME

	Year Ended December 31,
(in millions, except per share data)	2025	2024	2023
Revenues:
Net product sales	$2,833.9	$2,330.6	$1,860.6
Collaboration revenues	26.6	24.7	26.5
Total revenues	2,860.5	2,355.3	1,887.1
Operating expenses:
Cost of revenues	52.1	34.0	39.7
Research and development	1,015.7	731.1	565.0
Acquired in-process research and development	17.4	12.5	143.9
Selling, general, and administrative	1,156.2	1,007.2	887.6
Total operating expenses	2,241.4	1,784.8	1,636.2
Operating income	619.1	570.5	250.9
Other income (expense):
Unrealized (loss) gain on equity investments	(4.0)	(37.1)	28.4
Charges associated with convertible senior notes	—	(138.4)	—
Investment income and other, net	90.3	91.0	52.8
Total other income (expense), net	86.3	(84.5)	81.2
Income before provision for income taxes	705.4	486.0	332.1
Provision for income taxes	226.8	144.7	82.4
Net income	478.6	341.3	249.7
Foreign currency translation adjustments, net of tax	3.8	(1.1)	2.4
Unrealized gain (loss) on available-for-sale debt securities, net of tax	3.5	(0.1)	12.5
Comprehensive income	$485.9	$340.1	$264.6
Earnings per share, basic	$4.81	$3.40	$2.56
Earnings per share, diluted	$4.67	$3.29	$2.47
Weighted average common shares outstanding, basic	99.5	100.4	97.7
Weighted average common shares outstanding, diluted	102.5	103.7	101.0

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.